Screener
Vaxcyte, Inc. PCVX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of investments | (584,129) | (314,485) |
| Maturities of investments | 340,631 | 438,488 |
| Sales of investments | 24,882 | 26,065 |
| Net cash provided by (used in) investing activities | (233,410) | 123,317 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of shares through employee equity incentive plans | 9,032 | 6,049 |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | 601,846 | — |
| Taxes paid related to the net share settlement of equity awards | (9,295) | (5,290) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s investing cash flow?
- Vaxcyte, Inc. (PCVX) reported investing cash flow of -$233.41M in Q1 2026.
- How has Vaxcyte, Inc.'s investing cash flow changed year-over-year?
- Vaxcyte, Inc.'s investing cash flow decreased by 289.3% year-over-year, from $123.32M to -$233.41M.
- What is the long-term trend for Vaxcyte, Inc.'s investing cash flow?
- Over 3 years (2021 to 2025), Vaxcyte, Inc.'s investing cash flow has grown at a 27.2% compound annual growth rate (CAGR), from -$212.39M to $437.35M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Vaxcyte, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude